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Protocol
AbstrAct
Introduction Colorectal cancer is the fourth most common 
cancer in the UK and an important cause of cancer-related 
death. In 20% of patients, there is metastasis to the liver 
or beyond at the time of diagnosis. The management 
of synchronous disease is complex. Conventional 
surgery removes the colorectal primary first, followed by 
chemotherapy, with resection of liver metastases as a final 
step. Advances in the availability and safety of liver surgery, 
anaesthesia and critical care have made two alternative 
options feasible. The first is synchronous resection of the 
primary and liver metastases. The second is resection of 
the metastatic disease as the first step, termed the reverse 
or liver-first approach. Currently, evidence is inadequate 
to inform the selection of care pathway for patients with 
colorectal cancer and synchronous liver-limited metastases. 
Specifically, optimal pathways are not defined and there is 
a dearth of prospectively recorded cohort-defining factors 
influencing treatment selection or outcome.
Methods and analysis Colorectal cancer with Synchronous 
liver-limited Metastases: an Inception Cohort (CoSMIC) is an 
inception cohort study of patients with a new diagnosis of 
colorectal cancer with synchronous liver-limited metastases. 
The sequence of treatment received, and factors influencing 
treatment decisions, will be evaluated against European 
Society of Medical Oncology guidelines. Clinical data will be 
collected, and quality of life, morbidity, mortality and long-
term outcome compared for different treatment sequences 
adjusted for prognostic factors. Disease-free survival or 
progression will be measured at 1, 2 and 5 years. A nested 
qualitative study will ascertain patient experiences and 
clinician perspectives on delivery of care.
Ethics and dissemination The full study protocol was 
independently peer reviewed by Professor Kees de Jong 
(University of Maastricht, Holland). CoSMIC has ethical 
approval from the National Health Service Research Ethics 
Committee (14/NW/1397). Results will be disseminated to 
healthcare professionals and patient groups, and may be 
used to design a definitive trial addressing areas of equipoise 
in treatment pathways, as well as optimising current 
pathways to improve outcomes and experiences.
Trial registration number NCT02456285, pre-results.
Background
Bowel cancer is the fourth most common 
cancer in the UK.1 In Europe, colorectal 
cancer was the third most common cause 
of cancer and of cancer-related deaths in 
2012.2 The liver is the most frequent site of 
metastasis in colorectal cancer: 14%–20% 
of patients have hepatic metastases at 
presentation and up to a further third will 
subsequently develop liver lesions.3 4 Liver 
metastases in patients with colorectal cancer 
are categorised as stage IV disease in which 
overall 5-year survival is 6%.5 However, stage 
IV bowel cancer encompasses a wide clinical 
spectrum of disease ranging from patients 
with isolated hepatic metastases to patients 
with widespread metastatic disease. Patients 
with surgically resectable lesions confined to 
the liver have reported 5-year survival rates of 
25%–40%.6 Such patients represent a selected 
but important subgroup in whom long-term 
survival of approximately 17% at 10 years is 
feasible when the hepatic metastatic burden 
is removed.7
Patients who present with metastatic liver 
disease at a time point remote from their 
presentation with primary bowel cancer 
(termed metachronous disease) receive care 
focused on their new metastatic burden.8 9 In 
Strengths and limitations of this study
 ► This is the first prospective study directly comparing 
outcomes between the different surgical sequences 
of patients with colorectal cancer and liver-limited 
metastases.
 ► Completion of the Colorectal cancer with 
Synchronous liver-limited Metastases: the protocol 
of an Inception Cohort (CoSMIC) study protocol 
will provide important new evidence about the 
treatment of patients with colorectal cancer with 
synchronous liver-limited metastases and provide 
objective evidence to guide future studies (including 
randomised evaluations) in this area.
 ► The variables involved in the treatment allocation of 
such patients are vast and currently do not allow for 
a randomised controlled trial. The current CoSMIC 
study is therefore limited to an observational, 
inception cohort study.
group.bmj.com on June 13, 2017 - Published by http://bmjopen.bmj.com/Downloaded from 
2 Siriwardena AK, et al. BMJ Open 2017;7:e015018. doi:10.1136/bmjopen-2016-015018
Open Access 
contrast, the management of patients who present with 
colorectal cancer and concurrent liver metastases (termed 
synchronous metastases) are more complex.9 10 These 
patients may have less favourable cancer biology and thus 
may be less likely to become long-term survivors.11 Logi-
cally, the management of patients with colorectal cancer 
with synchronous metastases can be dichotomised into 
those with hepatic disease together with extrahepatic 
metastatic disease and those with liver-limited metastatic 
disease. In the first category, systemic chemotherapy is the 
mainstay of treatment advocated in current guidelines 
for patients with advanced multisite metastatic disease of 
colorectal cancer origin.9 12
The second category of patients with liver-limited 
synchronous metastases represents a common and 
increasingly complex clinical management problem.13 
Traditional management (referred to variously as the 
classical or staged approach) comprised resection of the 
colorectal primary tumour followed by adjuvant chemo-
therapy with liver resection being undertaken (if at 
all) as a subsequent operation.13–15 Key advances in the 
availability and safety of liver surgery, anaesthesia and crit-
ical care have made two alternative options feasible for 
patients with synchronous disease. The first is synchro-
nous resection of the liver metastases and the colorectal 
primary.13 15 This has the attraction of removing the 
macroscopic tumour burden with a single operation. 
However, the morbidity of complex liver resection 
combined with major bowel resection may be consider-
able and there is some evidence of a negative effect on 
progression-free survival.16 The second option is resection 
of the liver metastatic disease as the first step, termed the 
reverse or liver-first approach.17 18 Liver-first surgery may 
be particularly applicable to patients with rectal cancer 
with synchronous liver metastases where preoperative 
long-course chemoradiotherapy for the rectal primary 
prior to surgical resection creates a potential ‘window’ in 
which liver resection may be undertaken.19 20 The liver-
first strategy may also be oncologically advantageous by 
addressing the hepatic metastatic burden before progres-
sion in the liver renders this unresectable.21 A further 
potentially important benefit of the liver-first approach 
is that pelvic surgery may be either avoided or less exten-
sive in patients with rectal tumours with a complete 
endoscopic, radiological and clinical response to chemo-
radiotherapy.22
Currently, evidence is inadequate to inform the selec-
tion of care pathway for patients with colorectal cancer 
with synchronous liver-limited hepatic metastases. 
Specifically, there is a dearth of prospectively recorded 
cohort-defining factors influencing treatment selection 
or outcome. European Society of Medical Oncology 
(ESMO) guidelines9 provide only a framework for the 
management of these patients. In the UK’s National 
Health Service (NHS), treatment decisions are made 
at multidisciplinary cancer team (MDT) meetings that 
include liver surgeons, colorectal surgeons, oncologists 
and specialist nurses. Factors considered in formulating 
a treatment pathway include comorbidity and fitness for 
surgery, liver and colorectal disease distribution and the 
optimal placement of chemotherapy in the care plan.
Given the treatment permutations to be understood, 
an inception cohort study is valuable to understand 
patient outcomes as a function of clinical decisions and 
patient/disease characteristics. The Colorectal cancer 
with Synchronous liver-limited Metastases: an Incep-
tion Cohort (CoSMIC) study will recruit patients with 
colorectal cancer with synchronous liver-limited hepatic 
metastatic disease, and aims to fulfil four objectives. First, 
the study will characterise the management of this cohort 
by reporting relationships between modes of presenta-
tion, management and adherence to or deviation from 
current clinical guidelines. The second objective of the 
CoSMIC study is to provide (for the first time) compa-
rable outcome data on patients with colorectal cancer 
with liver-limited hepatic metastases treated by synchro-
nous or sequential surgery. The third objective is to 
address (also for the first time in a structured, prospec-
tive fashion) the impact of treatment on quality of life 
using validated questionnaire methodology. Finally, in 
this typically complex care plan, it may be difficult for 
the patients’ voice to be heard and given due consider-
ation. The focus on patient experience is important23 
and may vary substantially according to the treatment 
pathway. Thus, as a fourth objective a parallel qualitative 
study of both patient and clinician experience will help 
inform the knowledge of current practice. Completion 
of the CoSMIC study protocol will provide important 
new evidence about the treatment of patients with 
colorectal cancer with synchronous liver-limited metas-
tases and provide objective evidence to guide future 
studies (including randomised evaluations) in this area.
MeThods and analysis
aims of the study
The primary aims of the study are to
1. characterise the management of patients with 
colorectal cancer and synchronous liver metastases, 
thus defining the relationship between presentation 
and treatment to demonstrate adherence to or 
deviation from an evidence-informed common 
pathway. It is accepted that modern management 
of this complex clinical scenario cannot be 
sufficiently addressed by a single pathway but 
the guidelines suggested by ESMO provide 
constrained management options: these include 
early use of neoadjuvant chemotherapy, surgical 
resection and adjuvant chemotherapy as the final 
stage. The treatment options within the common 
pathway standardise initial staging, accommodating 
treatment for liver metastases according to liver 
involvement and location of disease as well as 
different treatment requirements for patients with 
rectal primary cancer compared with those with 
colonic primary tumours;
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2. provide comparable and prospective outcome 
data on patients with colorectal cancer with liver-
limited hepatic metastases treated by synchronous 
or sequential surgery;
3. address the impact of treatment on quality of life 
using validated questionnaire methodology;
4. understand and explore the patient and caregiver 
experience of their disease and their experiences 
through the treatment pathway, including their 
voice in treatment decision planning;
5. understand and explore the clinician’s experience 
of providing care to patients, and their perspectives 
on treatment pathways, specifically in areas of 
clinical equipoise, that make treatment allocation 
difficult;
6. explore the acceptability and barriers of a future 
randomised trial from both a clinician and patient’s 
perspective, with a focus on the ethical dilemmas 
and the potential clinical value of such a study.
design
An inception cohort study will evaluate the treatment 
and outcomes of patients with colorectal cancer with 
synchronous liver-limited hepatic metastases. A parallel 
phenomenological qualitative study will also explore 
the patient and caregiver experience of the disease and 
treatment, and separately, the clinician perspective of 
providing care.
setting
The study population will comprise patients with colorectal 
cancer with liver-limited hepatic metastases referred to 
the Hepatobiliary Surgical Unit at Manchester Royal 
Infirmary—an NHS regional cancer-network approved 
hepato-pancreato-biliary (HPB) centre with a formally 
constituted and National Cancer Network peer-review 
accredited MDT. The study opened for recruitment in 
April 2015 with prospective recruitment to be undertaken 
for 24 months.
Participants
To be eligible for inclusion in this cohort study, patients 
must fulfil the following:
Inclusion criteria
1. Over18 years of age
2. Able to give informed consent
3. Have a histological diagnosis of colorectal cancer
4. No prior history of malignancy.
5. Have radiological evidence on either contrast-
enhanced CT or contrast-enhanced MR scanning 
of hepatic metastases at the time of diagnosis of the 
primary tumour or within 3 months thereof. Liver 
metastases should not be biopsied.
6. CT and/or fluorodeoxyglucose positron emission 
tomography ([18F]FDG-PET) evidence of the 
absence of extrahepatic metastases
7. MR scan assessment of local stage in those patients 
with rectal primary tumours
8. WHO performance status 0, 1 or 2 and considered 
by the MDT to be suitable for chemotherapy
9. A subset of patients from the cohort will be selected 
by purposeful sampling for the qualitative study 
following completion of their treatment, and are 
able to take part in a structured interview
Exclusion criteria
1. Patients who are under 18 years of age
2. Patients who are unable to give informed consent
3. Patients who are unfit for the chemotherapy 
regimens in this protocol
4. Any psychiatric or neurological condition assessed 
by clinical judgement to compromise the patient's 
ability to give informed consent or to comply with 
oral medication
5. Partial or complete bowel obstruction not amenable 
to resolution by stent or diversion
6. Pre-existing neuropathy (> grade 1)
7. Patients with another previous or current malignant 
disease
8. Patients with known hypersensitivity reactions to 
any of the components of the study treatments
9. Patients with distant metastases outwith the liver
10. Patients who have received prior chemotherapy 
with oxaliplatin
11. Patients with a personal or family history suggestive 
of dihydropyrimidine dehydrogenase (DPD) 
deficiency or with known DPD deficiency
12. For patients selected for the qualitative study—
those who are unable to give consent or are unfit to 
take part in a structured interview
For the clinician arm of the qualitative study, clinicians 
must fulfil the following:
Inclusion criteria
1. Consultant grade
2. In clinical practice and an active participant of the 
HPB MDT in one of the following specialities: HPB 
surgery, colorectal surgery, radiology, oncology and 
histopathology
3. Willing to give informed consent
Exclusion criteria
1. Non-consultant grade
2. Not in clinical practice or an active participant of 
the HPB MDT
3. Unwilling to give informed consent
recruitment
Patients will be formally identified prospectively at the 
weekly regional HPB MDT and approached in the outpa-
tient clinic at MRI to discuss participation. Recruitment 
began in April 2015. For patients wishing to enrol, but 
where the treatment pathway has already started (typically 
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those who presented with an acute abdomen secondary to 
the bowel lesion), data will be retrospectively collected on 
treatment already received. Missing data points, particu-
larly quality of life prior to surgery, during data analysis 
will be compensated for by unit imputation.
Potential participants of qualitative study will be 
approached following completion of their treatment 
either in the outpatient clinic or by telephone to ascer-
tain their interest in taking part in the interviews.
data collection
Clinical data will be collected on the following baseline 
staging investigations and treatment details (box 1).
In addition to demographic detail, baseline staging 
will include tests for histological confirmation of 
cancer such as biopsy confirmation of a diagnosis of 
primary colorectal cancer (from the primary and not 
from the metastasis); tests for assessment of the liver 
and colorectal cancer in terms of lesion size, number, 
nodal involvement: contrast-enhanced CT scan and/
or contrast-enhanced MR scan of the liver and pelvis 
and tests for assessment of the presence or absence of 
extrahepatic metastatic disease such as [18F]FDG-PET 
scan and serum assay of carcinoembryonic antigen. All 
of these tests are components of standard clinical care 
and no additional tests are undertaken for research 
purposes.
Predictors of treatment allocation
Factors which guide clinical decision making in terms 
of the use of neoadjuvant chemotherapy and the choice 
of intervention (synchronous or sequential surgery).
Timelines for completion of the treatment protocol
For the purposes of this study, this is defined as the 
amount of time in days from enrolment to completion of 
the protocol. The term ‘protocol’ relates to completion 
of the common treatment pathway.
Failure to complete the treatment protocol
This is defined as dropout prior to completion of the 
allocated treatment sequence. It will be further catego-
rised as due to disease progression, patient choice or 
unrelated to colorectal cancer (for example myocar-
dial infarction) and will be recorded as the time in days 
from enrolment.
Disease-free survival 12 months after enrolment into protocol
This is defined as the absence of tumour on a CT scan 
of the thorax, abdomen and pelvis undertaken at the 
completion of the protocol. In the case of those patients 
with rectal tumours treated by a’ watch and wait ‘policy, 
the term disease free can only be applied if there is a 
combination of radiological, endoscopic and clinical 
evidence of absence of cancer.
Disease progression in patients who are not disease free at the 
end of protocol
The most sensitive measure of change is likely to involve a 
metric incorporating tumour size and number of lesions 
in the case of multiple metastases. There is evidence that 
CT-based volumetric assessment of metastases (seeded 
region growing method, slice-based segmentation or 
threshold-based segmentation) is more accurate for 
assessment of disease progression than the Response 
Evaluation Criteria In Solid Tumors (RECIST) V.1.1 
method of largest axial diameter.24 It is acknowledged 
that although RECIST criteria provide an objective means 
of assessment of solid tumour response to treatment, 
there is a risk of interobserver bias.25 Further, RECIST 
criteria may be insufficient to assess response to treat-
ment in patients with colorectal liver metastases treated 
Box 1 Baseline staging investigations and treatment 
details
Baseline characteristics
Patient demographics
Charlson comorbidity score
Blood tests (full blood count, serum urea and electrolytes, liver function 
tests, carcinoembryonic antigen)
Clinical presentation
Cancer stage at presentation
Location and stage (TNM/Dukes) of colorectal primary
Location, number and size of liver metastases
fluorodeoxyglucose positron emission tomography
Rectal MR (if applicable)
Preoperative workup
Portal vein embolisation 
Cardiopulmonary exercise test 
Surgery (staged/synchronous resections) 
Sequence of surgery 
Open/laparoscopic 
Operative time 
Estimated blood loss/transfusion
Bowel resection 
Primary anastomosis 
Covering stoma 
Liver resection 
Major resection (>3 Couinaud segments) 
Pringle time 
Complications (Clavien-Dindo) 
Critical care stay 
Total inpatient stay 
Readmission within 30 days 
30-day mortality 
Chemotherapy (neoadjuvant/adjuvant) 
Regime 
Number of cycles (planned/given) 
Duration of treatment 
Side effects (common terminology criteria for adverse events) 
Restaging 
Outcomes (1, 2 and 5 years) 
Disease-free survival 
Disease progression 
Quality of life 
EuroQol with 5 dimensions with 3 levels of severity (EQ-5D-3L) 
European Organization for Research and Treatment of Cancer Core 
Quality of Life Questionnaire (EORTC QLQ-C30) 
European Organization for Research and Treatment of Cancer 
Colorectal Cancer Liver Metastasis specific module (EORTC QLQ LMC)
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by biological agents such as bevacizumab.26 Thus, disease 
progression at end of protocol will be assessed both by 
RECIST V.1.1 criteria and volumetric assessment.
Resection margin status
The terms R0 bowel resection and R0 liver resection 
will be used (R0 means no tumour at or within 1 mm of 
surgical resection margin).27 28
Complication and treatment-related morbidity profiles
Complications will be recorded prospectively according to 
the criteria defined above (see treatments) and assessed at 
the end of the study. Operative outcomes will be reported 
in keeping with the Dindo-Clavien system of assessment of 
postoperative morbidity.29 The specific posthepatectomy 
complications of haemorrhage,30 bile leakage31 and liver 
failure32 will be recorded in compliance with the guid-
ance of the International Study Group of Liver Surgery. 
The morbidity associated with each intervention step will 
be recorded separately. Morbidity will include unplanned 
readmission and reoperation. Requirement for non-elective 
surgery for colonic complications (obstruction, perfora-
tion, bleeding) will be recorded.
Mortality
Overall and cancer-related mortality in either arm after 
enrolment will be recorded. Mortality (and cause) will 
be determined using the Demographics Batch Service to 
access the national electronic database of the UK NHS.
Use of stoma after colorectal surgery
Use of stoma (either temporary or permanent if this noti-
fication is available) will be recorded.
Inpatient and critical care occupancy
A record will be made of inpatient and critical care occu-
pancy associated with interventions; data will inform 
planning of economic evaluation in any subsequent 
randomised trial.
Quality of life
Quality of life (QoL) will be assessed using the European 
Organisation for Research and Treatment of Cancer Core 
Quality of Life (EORTC QLQ-C30) and colorectal cancer 
liver metastasis specific module (EORTC QLQ-LMC) 
questionnaires, which have been validated for assess-
ment of patient-reported outcomes during treatment of 
colorectal liver metastases.33 The questionnaire will be 
completed by patients at time of enrolment and at 12 and 
24 months. The EuroQoL questionnaire with 5 dimen-
sions with 3 levels of severity (EQ-5D-3L)34 will also be 
completed at the same time points, again supporting the 
design of future trial-based economic analyses.
Qualitative study interview guide
Structured interviews will last approximately 45 min, and 
explore (1) for patients and caregivers: the experience of 
disease, particularly through the treatment pathway; under-
standing and expectations of time frame for investigations; 
how they were informed of the diagnosis; how they received 
information related to the condition and treatment 
pathway; the type of information provided and who were 
the professionals explaining this; the nature and impact 
of information about diagnosis on patients and caregivers, 
and on their relationship with the clinician; aspects of 
the process patients and caregivers found useful/not so 
useful and what could be improved; and the acceptability 
of entering into a future randomised control trial; (2) for 
clinicians: their experience of providing care, in particular, 
the perspectives and their views on treatment pathways; 
difficulties and challenges around treatment allocation and 
decision-making processes; the relationship with patients; 
acceptability and barriers to entering patients who may be 
under their care into a future randomised trial; any ethical 
issues and the potential clinical value of future randomised 
control study.
data sources and measurements
Data will be collected prospectively using electronic study 
clinical case report forms. These will be anonymised and 
encrypted for storage and analysed prospectively during 
study to maximise data completion and resolve emergent 
problems in a timely fashion. The principal source of data 
will be the individual patient records. In addition, infor-
mation will be gained by direct interview with patients 
(for quality of life assessment) and by interview with clini-
cians (for MDT choice decisions). Vital status beyond 
the duration of the study will be determined through 
the Demographics Batch Service of the NHS. Data will 
be reported at the end of year 3 allowing for a minimum 
12 months outcome data in the entire cohort. It is also 
proposed (contingent on separate funding) that informa-
tion on outcome will be collected for up to 5 years from 
study commencement, providing an informative survival 
analysis of treatment options.
Qualitative interviews will be audio recorded and tran-
scribed verbatim.
study size
Based on clinical registers, the HPB unit at Manchester 
Royal Infirmary sees approximately 75 patients with 
colorectal cancer with synchronous liver-limited hepatic 
metastases per annum. As there are no study-related inter-
ventions, recruitment rates should be high and dropout 
low and is estimated to provide 150 patients in the 2-year 
recruitment period. A formal power calculation is not 
provided for this inception cohort study. Instead, the 
sample size is informed by the need to: provide stable esti-
mates of variance for a range of outcomes; explore the 
relationship between the treatment pathway and health 
outcomes; estimate acceptability and recruitment rates; 
and describe patient and clinician experiences.
Purposeful sampling will be used to select patients from 
the cohort for the qualitative study. It is estimated that a 
sample size of four to six patients per group and one to 
two clinicians will produce data saturation. However, we 
will continue to interview until data saturation is reached.
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analysis plan
The care of patients within the study pathway will be 
characterised by their principal treatment route as 
synchronous, liver first or bowel first. All patients will 
provide outcomes which will be included within analyses, 
grouped according to the treatment sequence received. 
Complication profiles in patients according to treatment 
group will be reported.
acknowledgement of selection bias
The liver metastases multidisciplinary team meeting at the 
Manchester Royal Infirmary is the sole forum approved by 
cancer commissioners for discussion of the care of patients 
with colorectal cancer liver metastases. The HPB unit 
guideline is that all patients with stage IV colorectal cancer 
should have their care reviewed at the MDT. However, it 
is acknowledged that there are several groups of patients 
who may bypass the MDT. In particular, patients with 
systemic disease ‘beyond liver’ may be referred for chemo-
therapy without consideration for liver surgery. From the 
patient’s perspective, this care pathway is appropriate. 
Similarly, patients who present to local MDTs with liver 
metastases who undergo bowel-first surgery but whose 
disease progresses rendering them unsuitable for consid-
eration for liver surgery will likely not be referred. For the 
purposes of reporting the CoSMIC data, these sources of 
patient loss to study will be acknowledged together with 
any potential for selection bias. Reporting will be prag-
matic and descriptive.
statistical methods
Summary characteristics of patients, patient care provided 
and patient outcomes reported. Treatment centre char-
acteristics will include measures of activity and surgical 
preference.
Exploratory analysis of process and clinical outcomes will 
be undertaken to explore the influence of patient, clinician, 
centre and treatment covariates, using regression model-
ling. Models will be subject to specification and robustness 
checks. Standard Generalised Linear Models (GLIM) and 
propensity score matching approaches will be compared 
with explore potential spectrum bias issues.
Interview transcripts will be managed by NVivo (QSR 
International, Melbourne, Australia) software. Interviews 
will be analysed thematically, using constant comparison35 
within a modified framework approach36 coding both 
‘horizontally’ (by coding each interview as a standalone 
hermeneutic unit) and ‘vertically’ (by scanning across the 
interviews for specific terms). Identified categories will 
be developed into a matrix of themes using mind-map-
ping techniques and a systematic cross-comparison will 
be undertaken to identify the similarities and differences 
between the different types of participant.
Withdrawal from study
Patients will be able to withdraw from the study at any 
point. Data collected up to point of withdrawal will be 
retained for use within analyses.
Quality control measures
Colorectal cancer cases and patients with liver metastases 
will have their care discussed at an appropriately consti-
tuted, UK cancer network-approved MDT.37
Quality control in radiological images
Cross-sectional imaging will comply with the recommen-
dations for cross-sectional imaging in cancer management 
of the Royal College of Radiologists.38 An independent 
consultant radiologist will head the radiology standards 
group.
Quality control in histopathological reporting
All histopathology reporting will be in compliance with 
the guidelines of the Royal College of Pathologists.39
health service cost of study
The clinical pathways within this study are cost neutral to 
the NHS as all the component steps are a part of current 
best practice. The study provides a structured template 
for progression through this pathway but all components 
are currently best standard care. Currently and in the 
near future, scientific and clinical equipoise are likely to 
be maintained. It will be possible to explore determinants 
of resource use within the common pathway as a study 
outcome.
adverse event reporting
Adverse events will be recorded, assessed for severity and 
attribution and reported in line with European Directive 
2001/20/EC. In addition, if the Quality of Life assess-
ment indicates that a patient is experiencing ‘extreme 
problems’ with their treatment, it would be an ethical 
duty of the CoSMIC research group to inform the clin-
ical team involved with the care of the patient. This may 
introduce bias in subsequent quality of life assessments, 
and will be made transparent in any publication of results 
by the CoSMIC group.
Individual interviews will be stopped if there is any sign 
of emotional distress by either the patient or their rela-
tives being interviewed. For any issues raised, with the 
patient’s consent, we will contact their clinical team to 
make them aware of these issues so they can be formally 
addressed.
disseMinaTion Policy
The results of CoSMIC will be presented at the appro-
priate conferences. Study outcome data will be set at 1, 
2 and 5 years. Following publication of the final results, 
anonymised raw data will be made available.
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